Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06629363 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

Study acronym: HAMABANK
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 15, 2035 to Apr 1, 2036
    • Start date: Jun 15, 2025 to Aug 1, 2025
    • Study title expanded, about 1 word
    v3
  2. Start date: Jan 15, 2025 to Jun 15, 2025v2 Show 4 more changesShow less
    • Primary endpoint revised
    • Primary and study completion dates: Jan 15, 2035 to Jun 15, 2035
    • Secondary endpoints revised (2)
    • Study description revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Trial Details
NCT Number NCT06629363
Lead Sponsor Centre Hospitalier de PAU
Conditions
(from sponsor)		 Malignant Hypertension
Related terms Hypertension, Hypertension, Malignant, Hypertensive Crisis
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov